Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. heart valve announces issuance of a patent for a pre mounted pre packaged sterilized dry heart valve
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Heart Valve Announces Issuance Of A Patent For A Pre Mounted Pre Packaged Sterilized Dry Heart Valve Articles & Analysis

56 news found

HTG Used for First Time in Congenital Heart Defect Surgery

HTG Used for First Time in Congenital Heart Defect Surgery

It was another first for EchoPixel when its Holographic Therapy Guidance (HTG) was used in a congenital heart surgery at Cincinnati Children’s Hospital Medical Center. The procedure was conducted with a new mini 4D transesophageal echocardiography (TEE), which generates real-time ultrasound images and can be used in patients as small as 11 pounds. A life-saving procedure Complete ...

ByEchoPixel, Inc.


Confluent Medical Technologies Announces Grand Opening of Costa Rica Expansion

Confluent Medical Technologies Announces Grand Opening of Costa Rica Expansion

Confluent Medical Technologies (Confluent), today announced the Grand Opening of the latest addition to their large scale manufacturing center of excellence in Alajuela, Costa Rica expanding their capacity for Nitinol processing and catheter manufacturing. This new facility will be co-located with the existing Confluent Costa Rica facility and will add an additional 66,000 square feet to this ...

ByConfluent Medical Technologies


Sonia Madigan of the Market Herald interviews CEO Wayne Paterson on the progress of Anteris Technologies

Sonia Madigan of the Market Herald interviews CEO Wayne Paterson on the progress of Anteris Technologies

Anteris Technologies (AVR) pauses trading as it plans for an upcoming capital raise On Thursday, the company entered a trading halt, pausing shares until Monday, August 2 It is unknown how much the company is planning to raise or where the funds will be spent On the market, Anteris last traded at $8.59 per share Anteris Technologies (AVR) has paused trading as it plans for an upcoming ...

ByAnteris Technologies Limited


Xeltis accelerating clinical trial program

Xeltis accelerating clinical trial program

Xeltis announced today that is planning to accelerate its clinical trial program for three restorative devices in parallel. CEO Eliane Schutte provided a sneak preview on Xeltis’ plans to an audience of investors and medtech companies at the Medtech and Diagnostics Forum organised by the investment bank Canaccord Genuity Capital Markets. Xeltis currently has three restorative devices in ...

ByXELTIS BV


T,C&A Lab Declares Capability of Biomedical Materials Testing

T,C&A Lab Declares Capability of Biomedical Materials Testing

Since the last few decades, biomedical materials have been extensively used in a lot of medical applications, such as tissue scaffolds, wound care, regenerative dentistry, bone graft, implantable devices and cosmetic surgery. Earlier this month, T,C&A Lab, a branch of Alfa Chemistry, announces to provide biomedical material testing service for customers worldwide who would like to ensure ...

ByAlfa Chemistry


InnovHeart raises $55 million in Series C financing to further develop the Trans-septal Saturn Transcatheter Mitral Valve Replacement System

InnovHeart raises $55 million in Series C financing to further develop the Trans-septal Saturn Transcatheter Mitral Valve Replacement System

Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater China. The transaction pulled in ...

ByInnovHeart Srl.


Anteris Technologies` 30-day data from in-human heart valve trial yields promising results

Anteris Technologies` 30-day data from in-human heart valve trial yields promising results

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF)'s Wayne Paterson tells Proactive about the 30-day follow-up data just in from the company’s flagship heart valve, currently being tested in humans for the first time. The valve solves the problem of younger and more active heart patients who need a valve that performs better and lasts longer, and Paterson says these latest clinical results ...

ByAnteris Technologies Limited


JenaValve Announces Strategic Investment and Licensing Agreement with Peijia Medical Limited

JenaValve Announces Strategic Investment and Licensing Agreement with Peijia Medical Limited

JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced a strategic investment and exclusive technology licensing agreement with Peijia Medical Limited (HKEX: 9996) in China. Under the terms of the agreement, Peijia has made a cash and equity investment in ...

ByJenaValve Technology, Inc.


Confluent Medical Announces Significant Strategic Investment From TPG

Confluent Medical Announces Significant Strategic Investment From TPG

Confluent Medical Technologies (“Confluent”), a leading materials science, development and manufacturing partner to medical device manufacturers (“OEMs”), today announced that TPG Capital, the private equity platform of alternative asset management firm TPG, has agreed to make a majority investment in the company. TPG Capital joins existing investor Ampersand Capital ...

ByConfluent Medical Technologies


BIOMODEX and Montreal Heart Institute Team Up to Develop 3D Printed Pulsatile Heart Models

BIOMODEX and Montreal Heart Institute Team Up to Develop 3D Printed Pulsatile Heart Models

BIOMODEX®, the leader in biorealistic haptic simulators for physician training and rehearsals, and the Montreal Heart Institute (MHI), a world-renowned, ultra-specialized cardiology center, announced they are partnering to develop a new cardiovascular training solution to help cardiologists rehearse and train for complex valve-in-valve procedures. The teams will collaborate to develop ...

ByBIOMODEX


Xeltis lands €15 million European financing from EIB

Xeltis lands €15 million European financing from EIB

The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will support the acceleration of clinical programmes for three of Xeltis’ revolutionary, restorative devices. The financing is being made available under the European Guarantee Fund (EGF), an EIB Group initiative in partnership with EU Member ...

ByXELTIS BV


JenaValve Announces First European Commercial Implants with the Trilogy™ Heart Valve System

JenaValve Announces First European Commercial Implants with the Trilogy™ Heart Valve System

JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. The procedures, which included treatment of both aortic regurgitation1 (AR) and aortic stenosis1 (AS), took place in multiple centers in Germany, marks the official start of the ...

ByJenaValve Technology, Inc.


You live and learn

You live and learn

To better understand the needs of new medical markets, it has great importance for us to directly talk to end users. One of these end users is Prof. Reuthebuch who is Deputy Senior Physician of Cardiac Surgery in the university hospital in Basel. Together with him, we have evaluated in which part of a transcatheter heart valve implantation our navigation technology could provide benefits. This ...

ByNDI Europe GmbH


CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification, announced the public availability of preliminary data abstracts from two separate endocarditis studies, including the REMOVE study, to be presented at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) annual meeting ...

ByCytoSorbents Corporation


Anteris appoints Chief Medical Officer

Anteris appoints Chief Medical Officer

Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces the appointment of the internationally recognized Interventional Cardiologist, Dr Chris Meduri MD MPH, as its Chief Medical Officer (CMO). Dr Meduri is a recognized leader in the field of valvular heart disease, serving as the national principle investigator of several valve trials and on numerous steering committees. He has ...

ByAnteris Technologies Limited


Puzzle Medical announces partnership with Patent Attorney Scott Talbot from U.S. firm Cooley LLP

Puzzle Medical announces partnership with Patent Attorney Scott Talbot from U.S. firm Cooley LLP

Puzzle Medical Devices Inc. is enthusiastic to partner with Patent Attorney C. Scott Talbot from Cooley LLP as it continues to grow its patent portfolio. Cooley LLP is the largest medical technology patent team in the US. Scott has more than two decades of experience in the medical technology industry, including with prosthetic heart valves, heart valve repair, orthopedic surgery, stents, blood ...

ByPuzzle Medical Devices Inc.


JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial

JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial

JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinical trial for the Trilogy™ Heart Valve System for severe symptomatic, high-surgical risk aortic regurgitation. Aortic regurgitation (AR) is a condition ...

ByJenaValve Technology, Inc.


First Five Patients Successfully Treated with atHeart Medical’s Novel reSept Atrial Septal Defect Occluder in U.S. IDE Pivotal Trial

First Five Patients Successfully Treated with atHeart Medical’s Novel reSept Atrial Septal Defect Occluder in U.S. IDE Pivotal Trial

atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder. ...

ByatHeart Medical


First Five Patients Successfully Treated

First Five Patients Successfully Treated

atHeart Medical announced today the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder. The initial patients were treated by Dr. Thomas Jones, Cardiac ...

ByatHeart Medical


Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To date, pediatric patients requiring right ventricular outflow tract (RVOT) reconstruction have been successfully implanted as part of the global, FDA-approved Xplore2/Pivotal study. ...

ByXELTIS BV

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT